CurrentEndo coverage · page 2 of 2

The Lancet

Briefs 41–60 of 60 CurrentEndo has covered from this journal, newest publication first

Latest from The Lancet

All coverage, newest first

Lancet20 May 2024
Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial
Randomized controlled trialObesity
Lancet18 May 2024
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
Randomized controlled trialT2D & other
Lancet7 Apr 2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Meta-analysisObesity
Lancet6 Apr 2024
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Meta-analysisObesity
Lancet28 Mar 2024
Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study
Cohort studyObesity
Lancet29 Feb 2024
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults
Meta-analysisObesity
Lancet22 Feb 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
Randomized controlled trialAdrenal
Lancet17 Oct 2023
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
Randomized controlled trialT1D
Lancet7 Oct 2023
Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial
Randomized controlled trialT2D & other
Lancet26 Jun 2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Randomized controlled trialT2D & other
Lancet26 Jun 2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Randomized controlled trialObesity
Lancet26 Jun 2023
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Randomized controlled trialT2D & other
Lancet26 Jun 2023
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Randomized controlled trialObesity
Lancet24 Jun 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Randomized controlled trialT2D & other
Lancet23 Jun 2023
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Randomized controlled trialT2D & other
Lancet22 Jun 2023
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Research articleT2D & other
Lancet5 May 2023
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
Randomized controlled trialT2D & other
Lancet21 Apr 2023
Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
Randomized controlled trialLipids & liver
Lancet14 Mar 2023
Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact
Guideline or statementT1D
Lancet13 Mar 2023
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Randomized controlled trialReproductive endocrine

All 60 Briefs in ExploreShowing Briefs 41–60 of 60, newest first